S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Incannex Healthcare Inc., a pharmaceutical preparations company, has filed for a transfer of its common stock listing from The Nasdaq Global Market to The Nasdaq Capital Market as of June 11, 2025. This move is part of the company’s strategy to comply with Nasdaq’s continued listing requirements.
The Delaware-incorporated and Australia-based company, known under the trading symbol (NASDAQ:IXHL), must satisfy Nasdaq Capital Market’s continued listing criteria, complete an online application, pay the required fee, and receive approval from Nasdaq staff to finalize the transfer.
Previously, Incannex discussed its non-compliance with Nasdaq’s listing standards in SEC filings on January 10, 2025, and April 25, 2025. The transfer to The Nasdaq Capital Market is aimed at addressing these compliance issues. If accepted, Incannex’s common stock will maintain its presence on Nasdaq under the same trading symbol.
This announcement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ. Factors include the possibility that the transfer application may not be accepted, the company may fail to meet Nasdaq Capital Market listing requirements, and other risks detailed in the company’s Annual Report and subsequent filings.
The company emphasizes that it has no obligation to update any forward-looking statements unless required by law. The information provided is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.